Are institutional investors happy with Collplant Biotechnologies (USA Stocks:CLGN) technical and fundamental indicators?
 | By Vlad Skutelnik | Macroaxis Story |
If you have been following Collplant you may be considering picking up. Let's check if persistent technical and fundamental indicators will continue to push the price to rise for Collplant Biotechnologies' institutional investors. The company current chance of distress is under 38 percent. Will institutional investors continue to be optimistic, or should we expect a sell-off?
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Ellen Johnson
Collplant Biotechnologies has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.2604, which signifies not very significant fluctuations relative to the market. Let's try to break down what Collplant's beta means in this case. As returns on the market increase, returns on owning Collplant Biotechnologies are expected to decrease at a much lower rate. During the bear market, Collplant Biotechnologies is likely to outperform the market. Although it is important to respect Collplant Biotechnologies historical returns, it is better to be realistic regarding the information on the equity's current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Collplant Biotechnologies technical indicators, you can presently evaluate if the expected return of 0.096% will be sustainable into the future. Collplant Biotechnologies right now shows a risk of 5.83%. Please confirm Collplant Biotechnologies total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power to decide if Collplant Biotechnologies will be following its price patterns.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Collplant Biotechnologies income statement, its balance sheet, and the statement of cash flows. Potential Collplant Biotechnologies investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Collplant Biotechnologies investors may use each financial statement separately, they are all related. The changes in Collplant Biotechnologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Collplant Biotechnologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Collplant Biotechnologies fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Collplant Biotechnologies performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Collplant Biotechnologies shares is the value that is considered the true value of the share. If the intrinsic value of Collplant is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Collplant Biotechnologies. Please read more on our fundamental analysis page. How effective is Collplant Biotechnologies in utilizing its assets?
Collplant Biotechnologies reports assets on its Balance Sheet. It represents the amount of Collplant resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Collplant Biotechnologies aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Collplant volatility, please check the breakdown of all its fundamentals.Are Collplant Biotechnologies Earnings Expected to grow?
The future earnings power of Collplant Biotechnologies involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Collplant Biotechnologies factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Collplant Biotechnologies stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Collplant expected earnings.
Collplant Biotechnologies Gross Profit
Collplant Biotechnologies Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Collplant Biotechnologies previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Collplant Biotechnologies Gross Profit growth over the last 10 years. Please check Collplant Biotechnologies' gross profit and other fundamental indicators for more details.
What is driving Collplant Biotechnologies Investor Appetite?
Collplant Biotechnologies reported the previous year's revenue of 15.64 M. Net Income was 237 K with profit before overhead, payroll, taxes, and interest of 13.64 M.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Collplant Biotechnologies. Please refer to our Terms of Use for any information regarding our disclosure principles.